Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas reduced its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 8.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,025 shares of the company’s stock after selling 1,074 shares during the quarter. Teacher Retirement System of Texas’ holdings in Protagonist Therapeutics were worth $582,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Bank of Montreal Can lifted its stake in shares of Protagonist Therapeutics by 4.5% in the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after acquiring an additional 270 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after purchasing an additional 278 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company’s stock valued at $58,000 after buying an additional 728 shares during the last quarter. WINTON GROUP Ltd grew its position in shares of Protagonist Therapeutics by 3.0% during the fourth quarter. WINTON GROUP Ltd now owns 26,768 shares of the company’s stock worth $1,033,000 after buying an additional 785 shares in the last quarter. Finally, State of Wyoming increased its stake in shares of Protagonist Therapeutics by 11.9% in the fourth quarter. State of Wyoming now owns 7,832 shares of the company’s stock worth $302,000 after buying an additional 832 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 10,000 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total value of $570,300.00. Following the completion of the transaction, the insider owned 83,892 shares in the company, valued at $4,784,360.76. This represents a 10.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Asif Ali sold 1,756 shares of the company’s stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total transaction of $80,776.00. Following the completion of the sale, the chief financial officer directly owned 61,065 shares of the company’s stock, valued at approximately $2,808,990. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on PTGX shares. Wall Street Zen raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, June 8th. Wedbush reiterated an “outperform” rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Citigroup initiated coverage on Protagonist Therapeutics in a research note on Tuesday, June 17th. They set a “buy” rating and a $72.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $66.10.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $55.32 on Wednesday. Protagonist Therapeutics, Inc. has a 1 year low of $32.50 and a 1 year high of $60.60. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of 73.76 and a beta of 2.26. The stock’s fifty day moving average is $50.52 and its two-hundred day moving average is $45.28.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.31. The company had revenue of $28.32 million for the quarter, compared to analysts’ expectations of $30.44 million. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. As a group, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.